Table 4. Factors examined for the effect on toxicity.

Variable	Proportion of patients with grade III–IV toxicity	P-value
Age ⩽58/>58 years	25/50 (50.0%)/33/52 (63.5%)	0.17
Gender male/female	30/54 (55.6%)/28/48 (58.3%)	0.78
ECOG 0/1–2	29/51 (56.9%)/29/51 (56.9%)	1.00
Locoregional/disseminated disease	14/28 (50.0%)/44/74 (59.5%)	0.39
Disease on one side/both sides of diaphragm	31/59 (52.5%)/27/43 (62.8%)	0.30
One–two metastatic sites/three or more	33/60 (55.0%)/25/42 (59.5%)	0.21
Up to three metastases/four or more	19/31 (61.3%)/39/71 (54.9%)	0.55
No liver involvement/liver involved	46/75 (61.3%) / 12/27 (44.4%)	0.13
No visceral involvement/visceral involvement	26/42 (61.9%)/32/60 (53.3%)	0.39
Normal LDH/abnormal LDH	34/60 (56.7%)/15/26 (57.7%)	0.78
Normal ALP/abnormal ALP	46/74 (62.2%)/9/21 (42.9%)	0.11
Normal liver indexes/abnormal liver indexes	32/59 (54.24%)/25/42 (59.52%)	0.45
No epithelial tumour markers/any marker positive	23/40 (57.5%)/35/62 (56.5%)	0.92
No drug dose reduction/doses reduced	39/70 (55.7%)/19/32 (59.4%)	0.73
CBDCA⩽AUC 8/CBDCA>AUC 8	33/58 (56.9%)/25/44 (56.8%)	0.99
CBDCA⩽AUC 9/CBDCA>AUC 9	39/71 (54.9%)/19/32 (61.3%)	0.55

Note: χ² test; P-values are reported. ECOG=Eastern Cooperative Oncology Group; AUC=area under the curve.